LONGLY CAPITAL
Integrated Financial and Industrial Support
With the aging population expanding and the uneven distribution of high-quality resources, the potential of the Chinese healthcare market has reached an unprecedented peak. It has become an enticing arena that attracts widespread interest.
As a responsible investor, Longly's commitment goes beyond basic financial investment. Our intention is to introduce the overseas companies we invest in to the Chinese market. We possess the capacity to provide a range of essential partnerships and resources to entrepreneurs post-investment, enabling them to flourish amidst intense competition.
Through comprehensive industry and market analysis, Longly offers both broad and detailed perspectives. This aids in shaping effective strategies for the invested entity, enabling rapid growth by leveraging unique strengths and distinctive features that set it apart from existing competitors.
Longly's business network spans across various sectors, encompassing CDMO/CROs, Grade 3 hospital management (tier 1 hospitals in China), product distributors, and licensing collaborators. This highlights Longly's comprehensive network and resources for successful business commercialization.
IND, NDA, and device approvals mark critical milestones in the progression of a biotech company. Expert connection Longly possess can be leveraged to provide more professional regulatory and industry opinion on the strategy for approval, ensuring the efficiency of the already time consuming compliance and regulatory process.
Sustaining healthcare businesses invariably demands ongoing funding. Longly will proactively aid in securing subsequent rounds of financing by connecting them with appropriate capital sources.